MedTrace Logo

Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers

NCT03873324 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2019-10-04

No results posted yet for this study

Summary

The planned study is to determine the safety and pharmacokinetic properties of CPL500036 compound after single and multiple (two weeks) administration in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

CPL500036 compound

IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).

DRUG

Placebo

matching placebo capsules

Sponsors & Collaborators

  • National Center for Research and Development, Poland

    collaborator OTHER

  • Celon Pharma SA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-20
Primary Completion
2019-09-16
Completion
2019-09-16

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03873324 on ClinicalTrials.gov